Clinical Observation of terlipressin combined with somatostatin and endoscopic hemostasis in the treatment of esophagogastric variceal bleeding in liver cirrhosis
Objective:To observe the clinical efficacy and hemostatic effect of terlipressin combined with somatostatin and endoscopic hemostasis for the treatment of esophagogastric variceal bleeding(EGVB)in liver cirrhosis.Methods:A total of 100 patients with EGVB admitted to our hospital between January 2021 and December 2023 were selected and divided into two groups according to the random number table method,with 50 patients in each group.The control group was given 0.25 µg/h somatostatin continuously pumped by a microinfusion pump for 24～72 hours;endoscopic hemostasis was also performed.The observation group was additionally administered terlipressin compared to the control group.The initial dose was 2 mg intravenously,and then 0.125 mg/h terlipressin was continuously pumped by a microinfusion pump for 24～72 hours until bleeding was effectively controlled.Clinical efficacy,hemostatic effect,nutritional indicators,complications,and adverse reactions were compared between the two groups.Results:The total effective treatment rates in the observation and control groups were 94.00％and 80.00％,respectively,and the difference was statistically significant(P＜0.05).The success rate of hemostasis within 24 h in the observation group was higher than that in the control group;the complete hemostasis time was shorter than that in the control group;and the blood transfusion volume was less than that in the control group,and the differences were statistically significant(P＜0.05).Before treatment,there was no difference in the hemoglobin(Hb)and albumin(ALB)levels between the two groups(P＞0.05).After treatment,Hb and ALB levels in both groups were higher than those before treatment(P＜0.05),and Hb and ALB levels in the observation group were significantly higher than those in the control group(P＜0.05).There were no differences in complications or adverse reactions between the two groups(P＞0.05).Conclusion:Terlipressin combined with somatostatin and endoscopic hemostasis can quickly stop bleeding and improve the nutritional status of patients with EGVB,and there are no serious complications and adverse reactions that are worthy of clinical promotion and application.
esophagogastric variceal bleeding in liver cirrhosisterlipressinSomatostatinadverse reactionshemoglobinendoscopic hemostasis
万方数据
维普
